p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. [electronic resource]
Producer: 20180723Description: 6629-6639 p. digitalISSN:- 1557-3265
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Apoptosis -- drug effects
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Drug Resistance, Neoplasm -- genetics
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Mechanistic Target of Rapamycin Complex 1 -- antagonists & inhibitors
- Mice
- Neuroblastoma -- drug therapy
- Proto-Oncogene Proteins c-mdm2 -- antagonists & inhibitors
- Pyrrolidines -- administration & dosage
- Sirolimus -- administration & dosage
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Tumor Suppressor Protein p53 -- genetics
- Xenograft Model Antitumor Assays
- para-Aminobenzoates -- administration & dosage
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.